


PHARMACEUTICAL 2022

iBio Inc. Rank 122 of 475









iBio Inc. Rank 122 of 475



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 53% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 304% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	104,597
Cost of Goods Sold	1,462
Intangible Assets	952
Liabilities, Current	6,645
Liabilities, Non-Current	0
Other Assets	32,791
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	31,755
Other Net Income	7,898
Property and Equipment	8,628
Research and Development	9,989
Revenues	2,371
Selling, General and Administrative Expense	22,031

Output Variable	Value in 1000 USD
Assets	146,968
Liabilities	38,400
Expenses	33,482
Stockholders Equity	108,568
Net Income	-23,213
Comprehensive Net Income	-23,213
Economic Capital Ratio	27%

